GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » Net Cash per Share

Epigenomics AG (Epigenomics AG) Net Cash per Share : $1.62 (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Epigenomics AG Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Epigenomics AG's Net Cash per Share for the quarter that ended in Jun. 2023 was $1.62.

The historical rank and industry rank for Epigenomics AG's Net Cash per Share or its related term are showing as below:

EPGNF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.49   Med: 14.46   Max: 374.07
Current: 1.03

During the past 13 years, the highest Price-to-Net-Cash Ratio of Epigenomics AG was 374.07. The lowest was 0.49. And the median was 14.46.

EPGNF's Price-to-Net-Cash is ranked better than
94.87% of 78 companies
in the Medical Diagnostics & Research industry
Industry Median: 7.43 vs EPGNF: 1.03

Epigenomics AG Net Cash per Share Historical Data

The historical data trend for Epigenomics AG's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG Net Cash per Share Chart

Epigenomics AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 66.76 26.74 6.46 29.82 5.64

Epigenomics AG Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.21 13.00 5.64 0.46 1.62

Competitive Comparison of Epigenomics AG's Net Cash per Share

For the Diagnostics & Research subindustry, Epigenomics AG's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigenomics AG's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Epigenomics AG's Price-to-Net-Cash falls into.



Epigenomics AG Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Epigenomics AG's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

Net Cash per Share (A: Dec. 2022 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(10.631-6.017-0)/0.81856
=5.64

Epigenomics AG's Net Cash per Share for the quarter that ended in Jun. 2023 is calculated as

Net Cash per Share (Q: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(3.883-2.501-0)/0.85328
=1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigenomics AG  (OTCPK:EPGNF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Epigenomics AG Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigenomics AG (Epigenomics AG) Business Description

Traded in Other Exchanges
Address
Geneststrasse 5, Berlin, BB, DEU, 10829
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines